Sep 26 |
PTC Therapeutics Huntington's disease candidate nabs FDA Fast Track status
|
Sep 26 |
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
|
Sep 12 |
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Sep 12 |
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
|
Aug 28 |
PTC Therapeutics to Participate at Upcoming Investor Conferences
|
Aug 26 |
PTC Therapeutics Has Upside Potential With Multiple Upcoming Catalysts, UBS Says
|
Aug 26 |
PTC Therapeutics rises as UBS restarts coverage with buy rating
|
Aug 19 |
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
|
Aug 10 |
PTC Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
Aug 9 |
PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
|